Centivax plans to get their first universal flu vaccine through a Phase I clinical trial; Portal Biotech will use their nanopore-based platform technology to deliver rapid, full-length, single-molecule protein characterization and expand its R&D, engineering, and data-science teams; and more. $372.5M: Series D for Schizophrenia and Alzheimer’s Psychosis TreatmentMapLight Therapeutics announced an oversubscribed $372.5 million […]
